Sun Pharma Advanced Research Co. Ltd. ((IN:SPARC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sun Pharma Advanced Research Co. Ltd. is conducting a Phase 1 study titled ‘A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors.’ The study aims to assess the safety and tolerability of SBO-154 in patients with advanced cancers who have not responded to standard treatments.
The intervention being tested is a biological treatment named SBO-154, administered intravenously at five different dose levels every three weeks. The purpose is to evaluate its effectiveness in treating advanced solid tumors.
This is an interventional study with a sequential intervention model and no masking, focusing primarily on treatment. The study is open-label, meaning both researchers and participants know the treatment being administered.
The study began on May 28, 2025, with the latest update submitted on August 29, 2025. These dates are crucial as they indicate the study’s progress and current status in the recruitment phase.
The update on this study could influence Sun Pharma’s stock performance by boosting investor confidence, especially if preliminary results show promise. In a competitive industry, advancements in cancer treatment can significantly impact market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.